» Articles » PMID: 39253613

From Mesenchymal Stem Cells to Their Extracellular Vesicles: Progress and Prospects for Asthma Therapy

Overview
Date 2024 Sep 10
PMID 39253613
Authors
Affiliations
Soon will be listed here.
Abstract

Asthma is a widespread public health concern, with an increasing incidence. Despite the implementation of current treatment strategies, asthma control, particularly for severe cases, remains suboptimal. Recent research has revealed the encouraging prospects of extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) as a viable therapeutic option for alleviating asthma symptoms. Therefore, the present review aims to provide an overview of the current progress and the therapeutic mechanisms of using MSC-derived EVs (MSC-EVs) for asthma treatment. Additionally, different administration approaches for EVs and their impacts on biodistribution and the curative outcomes of EVs are summarized. Notably, the potential benefits of nebulized inhalation of MSC-EVs are addressed. Also, the possibilities and challenges of using MSC-EVs for asthma treatment in clinics are highlighted. Overall, this review is intended to give new insight into the utilization of MSC-EVs as a potential biological drug for asthma treatment.

References
1.
Dong L, Wang Y, Zheng T, Pu Y, Ma Y, Qi X . Hypoxic hUCMSC-derived extracellular vesicles attenuate allergic airway inflammation and airway remodeling in chronic asthma mice. Stem Cell Res Ther. 2021; 12(1):4. PMC: 7789736. DOI: 10.1186/s13287-020-02072-0. View

2.
Peng Y, Deng X, Xu Z, Wu Z, Fu Q . Mesenchymal stromal cells and their small extracellular vesicles in allergic diseases: From immunomodulation to therapy. Eur J Immunol. 2023; 53(10):e2149510. DOI: 10.1002/eji.202149510. View

3.
Kaminsky D, Chapman D . Asthma and Lung Mechanics. Compr Physiol. 2020; 10(3):975-1007. DOI: 10.1002/cphy.c190020. View

4.
Zhu Y, Shi M, Monsel A, Dai C, Dong X, Shen H . Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther. 2022; 13(1):220. PMC: 9135389. DOI: 10.1186/s13287-022-02900-5. View

5.
Agache I, Rocha C, Beltran J, Song Y, Posso M, Sola I . Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75(5):1043-1057. DOI: 10.1111/all.14235. View